Avacta Group PLC

Avacta Group PLC is a clinical-stage biopharmaceutical company based in London, United Kingdom, focused on developing innovative cancer therapies and powerful diagnostics. The company has strategically transitioned to a pure-play oncology biopharmaceutical entity, aiming to improve healthcare outcomes through targeted cancer treatments. Its mission is to challenge current drug delivery methods and expand the reach of highly potent therapeutics with an unwavering commitment to eliminate cancer.

Avacta's core business revolves around its proprietary technology platforms: pre|CISION® and Affimer®. The pre|CISION® platform is a tumor-activated oncology delivery system designed to concentrate potent warheads in the tumor microenvironment while sparing healthy tissues, leveraging a tumor-specific protease (fibroblast activation protein or FAP). The company's pipeline includes lead program AVA6000 (faridoxorubicin), a Gen One pre|CISION® peptide drug conjugate of doxorubicin, which has completed Phase 1a and is currently in Phase 1b expansion cohorts for salivary gland cancer, triple-negative breast cancer, and soft tissue sarcoma. A second clinical candidate, AVA6103 (FAP-EXd), has also entered Phase 1 development, and a Gen 3 pre|CISION® pipeline leveraging dual payload technology is under development.

Recent notable developments for Avacta Group PLC include the appointment of Christina Coughlin, MD, PhD, as CEO, effective May 1, 2024. The company has been actively presenting new data for its pre|CISION® technology and AVA6103 at scientific conferences, such as AACR 2026, and anticipates further clinical data readouts for AVA6000 and AVA6103 in late 2025 and the first half of 2026. Avacta also entered a strategic collaboration with Tempus in October 2024 to advance AI-driven drug development in oncology and successfully raised £10 million in equity in March 2026 to support its drug development efforts.